Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 18:5:16805.
doi: 10.1038/srep16805.

First Experience of Ultrasound-guided Percutaneous Ablation for Recurrent Hepatoblastoma after Liver Resection in Children

Baoxian Liu  1 , Luyao Zhou  1 , Guangliang Huang  1 , Zhihai Zhong  2 , Chunlin Jiang  1 , Quanyuan Shan  1 , Ming Xu  1 , Ming Kuang  1   3 , Xiaoyan Xie  1
Affiliations

First Experience of Ultrasound-guided Percutaneous Ablation for Recurrent Hepatoblastoma after Liver Resection in Children

Baoxian Liu et al. Sci Rep. .

Erratum in

Abstract

This study aimed to summarize the first experience with ultrasound-guided percutaneous ablation treatment (PAT) for recurrent hepatoblastoma (HB) after liver resection in children. From August 2013 to October 2014, PAT was used to treat 5 children with a total of 8 recurrent HB (mean size, 1.4 ± 0.8 cm; size range, 0.7-3.1 cm), including 4 patients with 7 tumors in the liver and 1 patient with 1 tumor in the lung. Technical success was achieved in all patients (5/5, 100%). The complete ablation rate after the first ablation session was 80% (4/5) on a patient-by-patient basis and 87.5% (7/8) on a tumor-by-tumor basis. Only 1 patient developed a fever with temperature >39 °C; it lasted 4 days after radiofrequency ablation (RFA) and was resolved by conservative therapy. During the follow-up period, new intrahepatic recurrences after PAT were detected in two patients. One died due to tumor progression 4 months after ablation. The median overall survival time after PAT was 13.8 months. PAT is a safe and promising therapy for children with recurrent HB after liver resection, and further investigation in large-scale randomized clinical trials is required to determine its role in the treatment of this disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1. A 4-year-old girl with recurrent hepatoblastoma after initial liver resection.
Contrast-enhanced computer tomography (CT) shows a 3.1 cm recurrent tumor in the caudal lobe (a). After percutaneous ethanol injection (b), contrast-enhanced CT shows disappearance of the enhancement within the treated tumor (c).
Figure 2
Figure 2. Treatment flow chart.
Figure 3
Figure 3. Disease-free survival curve of patients after PAT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kremer N., Walther A. E. & Tiao G. M. Management of hepatoblastoma: an update. Curr Opin Pediatr 26, 362–369 (2014). - PubMed
    1. Koneru B. et al. Liver transplantation for hepatoblastoma. The American experience. Ann Surg 213, 118–121 (1991). - PMC - PubMed
    1. Horton J. D., Lee S., Brown S. R., Bader J. & Meier D. E. Survival trends in children with hepatoblastoma. Pediatr Surg Int 25, 407–412 (2009). - PubMed
    1. Tannuri A. C., Cristofani L. M., Teixeira R. A., Odone Filho V. & Tannuri U. New concepts and outcomes for children with hepatoblastoma based on the experience of a tertiary center over the last 21 years. Clinics (Sao Paulo) 70, 387–392 (2015). - PMC - PubMed
    1. Qiao G. L. et al. Predictors of survival after resection of children with hepatoblastoma: A single Asian center experience. Eur J Surg Oncol 40, 1533–1539 (2014). - PubMed

MeSH terms